Alcami Hired Will Isom as Laboratory Services VP
The pharmaceutical services provider tapped the industry veteran to oversee commercial strategy for its biologics labs.
Updated on Oct. 1, 2026 in People
Live Poll
Does a new corporate appointment increase your trust in the services provided by that company?
Alcami has appointed Will Isom as its new Vice President of Laboratory Services Sales. This leadership addition aims to strengthen the company's commercial organization and expand support for clients across its biologics portfolio.
Why it matters
The hire is designed to accelerate growth across Alcami's analytical services and biologics business by refining its commercial strategy. The appointment follows a push to better align client partnerships with the company's existing laboratory service capabilities.
Will Isom brings more than two decades of experience in biologics development and commercial strategy to the firm. The company is betting on this tenure to scale its analytical services and biologics division.
The players
Will Isom
An executive with over 20 years of experience in biologics development, previously serving in leadership roles at Charles River Laboratories and as the global commercial head at Texcell.
Alcami
A provider of contract development and manufacturing services for the pharmaceutical and biotechnology industries.
The details
Isom will lead Alcami's commercial strategy for laboratory services, a function recently created to bolster the firm's market presence. The role is positioned to integrate commercial operations with the company's technical analytical and biologics offerings, aiming to deepen client partnerships. His background spans executive leadership roles, including time as a Site Director at Charles River Laboratories and leading the global commercial organization at Texcell.
Timeline
Alcami announced the appointment of Will Isom on October 1, 2026.
Market Landscape
This move follows a documented industry trend of contract research organizations recruiting experienced veterans to tighten commercial alignment with technical service delivery. It signals a shift toward prioritizing specialized leadership to scale operations within the competitive biologics sector.
Operators in the biologics space should track how Alcami's new commercial leadership influences pricing and contract terms for analytical services. Competitive firms should anticipate more aggressive client acquisition efforts from Alcami in the coming quarters.
The takeaway
The appointment of a long-term veteran like Isom signals an organizational pivot toward more structured commercial outreach. Operators should monitor whether this leadership change results in faster service onboarding times for their own biologics development projects.
Further reading
For more on executive leadership shifts, visit our People section.
Source note: This article includes information reported by Manufacturingchemist.
Live Poll
Does a new corporate appointment increase your trust in the services provided by that company?
